Top

Annals of Surgical Oncology

Published in:

01-01-2012 | Colorectal Cancer

Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma

Authors: Xianzheng Li, BSc, Jianmei Wang, BSc, Xiaojing Zhang, MSc, Yuanfeng Zeng, PhD, Li Liang, PhD, Yanqing Ding, MD

Published in: Annals of Surgical Oncology | Issue 1/2012

Abstract

Background

RhoGDI2 has been identified as a regulator of tumor metastasis but its role in cancer remains controversial. The aims of this study were to analyze the function of RhoGDI2 in colorectal carcinoma (CRC), and to determine its possible signaling pathway in CRC.

Methods

The expression of RhoGDI2 was detected in CRC cell lines, and 20 matched pairs of fresh CRC tissues, and 120 cases of clinical paraffin-embedded CRC tissues by real-time RT-PCR, Western blot, RT-PCR, or immunohistochemistry. The levels of activations of p-PI3K, p-Akt, p-MAPK, and p-MEK were then examined in RhoGDI2-overexpressing cells by Western blot. A series of assays were finally performed to evaluate the effect of RhoGDI2 on CRC cell behaviors in vitro.

Results

RhoGDI2 expression was higher in highly metastatic CRC cell lines than in lowly metastatic ones. RhoGDI2 expression was up-regulated in CRC or lymphatic metastatic tissues relative to normal mucosa (P < 0.05). RhoGDI2 expression was correlated strongly with tumor size, differentiation, and Duke’s stage (P < 0.05). Patients with lower RhoGDI2 expression had better overall survival (P = 0.012), and RhoGDI2 could predict prognosis only in patients with early-stage disease. High levels of activations of p-PI3K and p-Akt were observed in RhoGDI2-overexpressing cells. LY294002 inhibitor could abrogate the activation of PI3K/Akt pathway in those cells. Over-expression of RhoGDI2 enhanced CRC cell proliferation, motility, and invasion in vitro.

Conclusions

Over-expression of RhoGDI2 is associated with poor overall survival in CRC patients, especially those presenting in early-stage. RhoGDI2 contributes to cell proliferation, motility, and invasion of CRC, at least in part, by activating the PI3K/Akt pathway

Available only for authorised users

Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003;3:55–63.PubMedCrossRef

Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61:561–9.PubMed

Liang JT, Cheng YM, Chang KJ, Chien CT, Hsu HC. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes’ B2 rectal cancer after curative resection. Hepatogastroenterology. 1999;46:830–7.PubMed

Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed

Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133–42.PubMedCrossRef

Lozano E, Betson M, Braga VM. Tumor progression: small GTPases and loss of cell-cell adhesion. Bioessays. 2003;25:452–63.PubMedCrossRef

Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295–322.PubMedCrossRef

Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J. 2005;390:1–9.PubMedCrossRef

DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005;15:356–63.PubMedCrossRef

10.

Hart MJ, Maru Y, Leonard D, Witte ON, Evans T, Cerione RA. A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science. 1992;258:812–5.PubMedCrossRef

11.

Chuang TH, Xu X, Knaus UG, Hart MJ, Bokoch GM. GDP dissociation inhibitor prevents intrinsic and GTPase activating protein-stimulated GTP hydrolysis by the Rac GTP-binding protein. J Biol Chem. 1993;268:775–8.PubMed

12.

Fukumoto Y, Kaibuchi K, Hori Y, Fujioka H, Araki S, Ueda T, Kikuchi A, Takai Y. Molecular cloning and characterization of a novel type of regulatory protein (GDI) for the Rho proteins, ras p21-like small GTP-binding proteins. Oncogene. 1990;5:1321–8.PubMed

13.

Scherle P, Behrens T, Staudt LM. Ly-GDI, a GDP dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes. Proc Natl Acad Sci USA. 1993;90:7568–72.PubMedCrossRef

14.

Zalcman G, Closson V, Camonis J, Rousseau-Merck MF, Tavitian A, Olofsson B. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J Biol Chem. 1996;271:30366–74.PubMedCrossRef

15.

Lelias JM, Adra CN, Wulf GM, Guillemot JC, Khagad M, Caput D, Lim B. cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc Natl Acad Sci USA. 1993;90:1479–83.PubMedCrossRef

16.

Cho HJ, Baek KE, Yoo J. RhoGDI2 as a therapeutic target in cancer. Expert Opin Ther Targets. 2010;14:67–75.PubMedCrossRef

17.

Tapper J, Kettunen E, El-Rifai W, Seppälä M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001;128:1–6.PubMedCrossRef

18.

Zhang Y, Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res. 2006;66:5592–8.PubMedCrossRef

19.

Cho HJ, Baek KE, Park SM, Kim IK, Choi YL, Cho HJ, Nam IK, Hwang EM, Park JY, Han JY, Kang SS, Kim DC, Lee WS, Lee MN, Oh GT, Kim JW, Lee CW, Yoo J. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin Cancer Res. 2009;15:2612–9.PubMedCrossRef

20.

Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002;62:6418–23.PubMed

21.

Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004;10:3800–6.PubMedCrossRef

22.

Ma L, Xu G, Sotnikova A, Szczepanowski M, Giefing M, Krause K, Krams M, Siebert R, Jin J, Klapper W. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Br J Haematol. 2007;139:217–23.PubMedCrossRef

23.

Zhou J, Wang S, Lu J, Li J, Ding Y. Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. Int J Cancer. 2009;124:1879–86.PubMedCrossRef

24.

Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG. Validation of a model of colon cancer progression. J Pathol. 2000;192:446–54.PubMedCrossRef

25.

Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis. 2000;18:519–25.PubMedCrossRef

26.

Zhang Y, Rivera Rosado LA, Moon SY, Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem. 2009;284:12956–65.PubMedCrossRef

27.

Moon HG, Jeong SH, Ju YT, Jeong CY, Lee JS, Lee YJ, Hong SC, Choi SK, Ha WS, Park ST, Jung EJ. Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat. 2010;42:151–6.PubMedCrossRef

28.

Moissoglu K, McRoberts KS, Meier JA, Theodorescu D, Schwartz MA. Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Res. 2009;69:2838–44.PubMedCrossRef

29.

Schunke D, Span P, Ronneburg H, Dittmer A, Vetter M, Holzhausen HJ, Kantelhardt E, Krenkel S, Müller V, Sweep FC, Thomssen C, Dittmer J. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res. 2007;67:10694–702.PubMedCrossRef

30.

Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci USA. 2009;106:5807–12.PubMedCrossRef

31.

Zheng Z, Li J, He X, Chen X, Yu B, Ji J, Zhang J, Wang T, Gu Q, Zhu Z, Liu B. Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil. Hepatogastroenterology. 2010;7:1106–12.

32.

Niu H, Li H, Xu C, He P. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep. 2010;24:465–71.PubMed

33.

Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603.PubMedCrossRef

34.

Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.PubMed

35.

Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.PubMedCrossRef

36.

Brzezianska E, Pastuszak-Lewandoska D. A mini-review: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci. 2011;16:422–39.PubMedCrossRef

37.

Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol. 2007;39:2153–60.PubMedCrossRef

38.

Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem. 1998;273:200–6.PubMedCrossRef

39.

Park JS, Park JH, Khoi PN, Joo YE, Jung YD. MSP-induced RON activation up-regulates uPAR expression and cell invasiveness via MAPK, AP-1 and NF-κB signals in gastric cancer cells. Carcinogenesis. 2011;32:175–81.PubMedCrossRef

40.

Wang H, Quah SY, Dong JM, Manser E, Tang JP, Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922–6.PubMedCrossRef

Title: Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma
Authors: Xianzheng Li, BSc
Jianmei Wang, BSc
Xiaojing Zhang, MSc
Yuanfeng Zeng, PhD
Li Liang, PhD
Yanqing Ding, MD
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1944-4

At a glance: The STEP trials

Springer Medicine

Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Postoperative Pancreatic Fistula and the Risk Factors of Laparoscopy-Assisted Distal Gastrectomy for Early Gastric Cancer

The Diagnostic Values of Ultrasound and Ultrasound-Guided Fine Needle Aspiration in Subcentimeter-Sized Thyroid Nodules

Robotic Coloanal Anastomosis with or without Intersphincteric Resection for Low Rectal Cancer: Starting with the Perianal Approach Followed by Robotic Procedure

Neoadjuvant Chemotherapy Is Associated with Improved Survival Compared with Adjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer Only after Complete Pathologic Response

Is Intraperitoneal Chemotherapy After Cytoreductive Surgery Efficient? Knowing Whether It Is or Not Appears Secondary!

Simultaneous Medullary and Papillary Thyroid Cancer: A Novel Entity?